It is about a great result of a huge scientific relevance and a possible practical application. It is the first report at world level on antitumor activity of an inhibting peptide of kinase casein enzyme 2 (CK2), based on the induction of cellular death (apoptosis) for such period.

The work is technically well conceived, designed and executed. It was made the cselection of the most relevant peptide in this assay, its posterior fusion with a sequence from IHV of intracellular penetration and the evaluation of in vitro activity of peptide-quimera.

Peptide-quimera, called P15-Tat, showed in vitro selective cytotoxicity on neoplasic cells and apoptosis induction. This peptide produced in vivo mouse tumor regresion.

This work gave origin to a patent (in international phase already)as well as a publication in the prestigious and selective “Cancer Research”.

Taking into account that CK2-mediated phosphorylating increased in brain, prostate, breast, colon, lung and neck of the womb tumors, this peptide of original design and sequence, patented by the Center for Biotechnology and Genetic Engineering, constitutes a very important antitumor drug candidate.